These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

258 related items for PubMed ID: 22530607

  • 1. Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin.
    Valenti L, Aghemo A, Stättermayer AF, Maggioni P, De Nicola S, Motta BM, Rumi MG, Dongiovanni P, Ferenci P, Colombo M, Fargion S.
    Aliment Pharmacol Ther; 2012 Jun; 35(12):1434-42. PubMed ID: 22530607
    [Abstract] [Full Text] [Related]

  • 2. IL28B polymorphism as a predictor of antiviral response in chronic hepatitis C.
    Cieśla A, Bociąga-Jasik M, Sobczyk-Krupiarz I, Głowacki MK, Owczarek D, Cibor D, Sanak M, Mach T.
    World J Gastroenterol; 2012 Sep 21; 18(35):4892-7. PubMed ID: 23002361
    [Abstract] [Full Text] [Related]

  • 3. PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.
    Ampuero J, Del Campo JA, Rojas L, García-Lozano JR, Solá R, Andrade R, Pons JA, Navarro JM, Calleja JL, Buti M, González-Escribano MF, Forns X, Diago M, García-Samaniego J, Romero-Gómez M.
    Ann Hepatol; 2014 Sep 21; 13(4):356-63. PubMed ID: 24927606
    [Abstract] [Full Text] [Related]

  • 4. Prevalence of IFNL3 rs4803217 single nucleotide polymorphism and clinical course of chronic hepatitis C.
    Świątek-Kościelna B, Kałużna E, Strauss E, Nowak J, Bereszyńska I, Gowin E, Wysocki J, Rembowska J, Barcińska D, Mozer-Lisewska I, Januszkiewicz-Lewandowska D.
    World J Gastroenterol; 2017 Jun 07; 23(21):3815-3824. PubMed ID: 28638221
    [Abstract] [Full Text] [Related]

  • 5. Insulin resistance predicts sustained virological response to treatment of chronic hepatitis C independently of the IL28b rs12979860 polymorphism.
    Del Campo JA, Ampuero J, Rojas L, Conde M, Rojas A, Maraver M, Millán R, García-Valdecasas M, García-Lozano JR, González-Escribano MF, Romero-Gómez M.
    Aliment Pharmacol Ther; 2013 Jan 07; 37(1):74-80. PubMed ID: 23121166
    [Abstract] [Full Text] [Related]

  • 6. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI, Soriano V, Naggie S, Restrepo C, Goldstein D, Vispo E, McHutchison J, Benito JM.
    AIDS; 2011 May 15; 25(8):1025-33. PubMed ID: 21505315
    [Abstract] [Full Text] [Related]

  • 7. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
    Chen MY, Liu CH, Chen TC, Su TH, Chen PJ, Chen DS, Kao JH, Liu CJ.
    J Gastroenterol Hepatol; 2014 Jan 15; 29(1):102-9. PubMed ID: 23829453
    [Abstract] [Full Text] [Related]

  • 8. Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.
    Torres-Cornejo A, Ruiz-Valderas R, Jimenez-Jimenez L, Abad-Molina C, Gutierrez-Valencia A, Viciana P, Lopez-Cortes LF.
    J Viral Hepat; 2014 Mar 15; 21(3):178-88. PubMed ID: 24438679
    [Abstract] [Full Text] [Related]

  • 9. Relevance of low viral load in haemodialysed patients with chronic hepatitis C virus infection.
    Sperl J, Frankova S, Senkerikova R, Neroldova M, Hejda V, Volfova M, Merta D, Viklicky O, Spicak J, Jirsa M.
    World J Gastroenterol; 2015 May 14; 21(18):5496-504. PubMed ID: 25987772
    [Abstract] [Full Text] [Related]

  • 10. [Association of interleukin 28B polymorphisms with response to pegylatedinterferon plus ribavirin therapy for chronic hepatitis C].
    Xu H, Guo LL, He LL, Chen Y, Liu K, Lei BJ, Lei XZ.
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2012 Nov 14; 43(6):855-9. PubMed ID: 23387213
    [Abstract] [Full Text] [Related]

  • 11. Strong prediction of virological response to combination therapy by IL28B gene variants rs12979860 and rs8099917 in chronic hepatitis C genotype 4.
    Ragheb MM, Nemr NA, Kishk RM, Mandour MF, Abdou MM, Matsuura K, Watanabe T, Tanaka Y.
    Liver Int; 2014 Jul 14; 34(6):890-5. PubMed ID: 24102823
    [Abstract] [Full Text] [Related]

  • 12. Association between CXCL10 and DPP4 Gene Polymorphisms and a Complementary Role for Unfavorable IL28B Genotype in Prediction of Treatment Response in Thai Patients with Chronic Hepatitis C Virus Infection.
    Thanapirom K, Suksawatamnuay S, Sukeepaisarnjaroen W, Tangkijvanich P, Treeprasertsuk S, Thaimai P, Wasitthankasem R, Poovorawan Y, Komolmit P.
    PLoS One; 2015 Jul 14; 10(9):e0137365. PubMed ID: 26339796
    [Abstract] [Full Text] [Related]

  • 13. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
    Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A.
    Arch Virol; 2015 Aug 14; 160(8):2009-17. PubMed ID: 26060059
    [Abstract] [Full Text] [Related]

  • 14. High resolution melting curve assay for detecting rs12979860 IL28B polymorphisms involved in response of Iranian patients to chronic hepatitis C treatment.
    Fateh A, Aghasadeghi MR, Keyvani H, Mollaie HR, Yari S, Hadizade Tasbiti AR, Ghazanfari M, Monavari SH.
    Asian Pac J Cancer Prev; 2015 Aug 14; 16(5):1873-80. PubMed ID: 25773839
    [Abstract] [Full Text] [Related]

  • 15. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection.
    Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, Chang SW, Sheen IS.
    PLoS One; 2011 Mar 30; 6(3):e18322. PubMed ID: 21479134
    [Abstract] [Full Text] [Related]

  • 16. Role of interleukin 28B-related gene polymorphisms in chronic hepatitis C and the response to antiviral therapy in Koreans.
    Jung YK, Kim JH, Ahn SM, Yang JW, Park SJ, Kim JW, Yeon JE, Kwon OS, Kim YS, Choi DJ, Kim JH, Byun KS.
    J Clin Gastroenterol; 2013 Aug 30; 47(7):644-50. PubMed ID: 23442843
    [Abstract] [Full Text] [Related]

  • 17. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
    Lindh M, Lagging M, Arnholm B, Eilard A, Nilsson S, Norkrans G, Söderholm J, Wahlberg T, Wejstål R, Westin J, Hellstrand K.
    J Viral Hepat; 2011 Jul 30; 18(7):e325-31. PubMed ID: 21692944
    [Abstract] [Full Text] [Related]

  • 18. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
    Itokawa N, Atsukawa M, Tsubota A, Kondo C, Hashimoto S, Fukuda T, Matsushita Y, Kidokoro H, Kobayashi T, Narahara Y, Nakatsuka K, Kanazawa H, Iwakiri K, Sakamoto C.
    J Gastroenterol Hepatol; 2013 Mar 30; 28(3):443-9. PubMed ID: 23173698
    [Abstract] [Full Text] [Related]

  • 19. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy.
    Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, Miki D, Imamura M, Ochi H, Kamatani N, Nakamura Y, Chayama K.
    Gut; 2011 Feb 30; 60(2):261-7. PubMed ID: 21068134
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-28B polymorphisms on the SVR in the treatment of naïve chronic hepatitis C with pegylated interferon-α plus ribavirin: a meta-analysis.
    Shi KQ, Liu WY, Lin XF, Fan YC, Chen YP, Zheng MH.
    Gene; 2012 Oct 01; 507(1):27-35. PubMed ID: 22842190
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.